Multiple Myeloma Awareness Month: When the Doctor Becomes the Caregiver

Read More

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

Briere et al.
Cancer Immunology
Immunotherapy
November 2017
Authors and Affiliates
David Briere1, Niranjan Sudhakar1, David M. Woods2, Jill Hallin1, Lars D. Engstrom1, Ruth Aranda1, Harrah Chiang1, Andressa L. Sodré2, Peter Olson1, Jeffrey S. Weber2, James G. Christensen1 1Mirati Therapeutics, Inc., 9393 Towne Center Dr, Suite 200, San Diego, CA 92121, 2NYU Langone Medical Center, New York, NY 10016, USA